Advertisement

NeuroMolecular Medicine

, Volume 20, Issue 4, pp 498–503 | Cite as

Plasma β-Amyloids and Tau Proteins in Patients with Vascular Cognitive Impairment

  • Sung-Chun Tang
  • Kai-Chien Yang
  • Chih-Hao Chen
  • Shieh-Yueh Yang
  • Ming-Jang Chiu
  • Chau-Chung Wu
  • Jiann-Shing Jeng
Original Paper
  • 554 Downloads

Abstract

Increases in plasma of β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer’s dementia (AD). Our study investigated the associations of plasma Aβ and tau proteins with dementia in stroke patients. This cross-sectional study recruited 24 controls (mean age: 67.4 ± 7.5 years, 33.3% male), 27 stroke patients without dementia (mean age: 70.7 ± 6.9 years, 60.7% male), 34 stroke patients with dementia (mean age: 78.3 ± 5.3 years, 45.5% male, Clinical Dementia Ranking (CDR): 1.46 ± 0.63), and 21 AD patients (mean age: 77.1 ± 9.1 years, 42.9% male, CDR: 1.43 ± 0.60) from a medical center. Dementia was defined as a CDR scale score of ≥ 1. The plasma levels of Aβ-40, Aβ-42, and tau were analyzed using immunomagnetic reduction. One-way analysis of variance was used to compare the differences in measured protein levels between the groups. The results indicated that plasma levels of tau and Aβ-42, but not Aβ-40, in stroke patients were significantly higher than in the controls. After adjustment for age, sex, diabetes mellitus, hypertension, and hyperlipidemia, only plasma level of Aβ-42 remained significantly higher in stroke patients with dementia than in those without dementia (OR 1.85, 1.25–2.75, p = 0.002). In summary, our results suggest that plasma Aβ-42 is a potential biomarker for dementia in stroke patients.

Keywords

Stroke Vascular dementia Amyloid beta Tau protein 

Notes

Acknowledgements

The authors thank the 3rd core facility at National Taiwan University Hospital for support.

Funding

This work was supported by Taiwan Ministry of Science and Technology Grant (105-2314-B-002-001).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. Chiu, M. J., Yang, S. Y., Horng, H. E., Yang, C. C., Chen, T. F., Chieh, J. J., et al. (2013). Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chemical Neuroscience, 4(12), 1530–1536.  https://doi.org/10.1021/cn400129p.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Feigin, V. L., Mensah, G. A., Norrving, B., Murray, C. J., & Roth, G. A. (2015). Atlas of the Global Burden of Stroke (1990–2013): The GBD 2013 Study. Neuroepidemiology, 45(3), 230–236.  https://doi.org/10.1159/000441106.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Huang, K. L., Lin, K. J., Ho, M. Y., Chang, Y. J., Chang, C. H., Wey, S. P., et al. (2012). Amyloid deposition after cerebral hypoperfusion: Evidenced on [(18)F]AV-45 positron emission tomography. Journal of the Neurological Sciences, 319(1–2), 124–129.  https://doi.org/10.1016/j.jns.2012.04.014.CrossRefPubMedGoogle Scholar
  4. Iadecola, C. (2013). The pathobiology of vascular dementia. Neuron, 80(4), 844–866.  https://doi.org/10.1016/j.neuron.2013.10.008.CrossRefPubMedGoogle Scholar
  5. Iqbal, K., Liu, F., & Gong, C. X. (2016). Tau and neurodegenerative disease: The story so far. Nature Reviews Neurology, 12(1), 15–27.  https://doi.org/10.1038/nrneurol.2015.225.CrossRefPubMedGoogle Scholar
  6. Jack, C. R. Jr., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., et al. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 257–262.  https://doi.org/10.1016/j.jalz.2011.03.004.CrossRefGoogle Scholar
  7. Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430(7000), 631–639.  https://doi.org/10.1038/nature02621.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., et al. (1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43(2), 250–260.CrossRefGoogle Scholar
  9. Tang, S. C., Jen, H. I., Lin, Y. H., Hung, C. S., Jou, W. J., Huang, P. W., et al. (2015). Complexity of heart rate variability predicts outcome in intensive care unit admitted patients with acute stroke. Journal of Neurology, Neurosurgery, and Psychiatry, 86(1), 95–100.CrossRefGoogle Scholar
  10. Tang, S. C., Wang, Y. C., Li, Y. I., Lin, H. C., Manzanero, S., Hsieh, Y. H., et al. (2013). Functional role of soluble receptor for advanced glycation end products in stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(3), 585–594.  https://doi.org/10.1161/atvbaha.112.300523.CrossRefPubMedGoogle Scholar
  11. Tang, S. C., Yang, K. C., Hu, C. J., Chiou, H. Y., Wu, C. C., & Jeng, J. S. (2017). Elevated plasma level of soluble form of RAGE in ischemic stroke patients with dementia. Neuromolecular Medicine, 19(4), 579–583.  https://doi.org/10.1007/s12017-017-8471-9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Thiel, A., Cechetto, D. F., Heiss, W. D., Hachinski, V., & Whitehead, S. N. (2014). Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke, 45(9), 2825–2829.  https://doi.org/10.1161/strokeaha.114.004285.CrossRefPubMedGoogle Scholar
  13. Tierney, M. C., Snow, W. G., & Fisher, R. H. (1989). Dementia diagnosis. Neurology, 39(11), 1559–1560.CrossRefGoogle Scholar
  14. Van Nostrand, W. E., Davis, J., Previti, M. L., & Xu, F. (2012). Clearance of amyloid-beta protein deposits in transgenic mice following focal cerebral ischemia. Neurodegenerative Diseases, 10(1–4), 108–111.  https://doi.org/10.1159/000334763.CrossRefPubMedGoogle Scholar
  15. Yang, S. Y., Chiu, M. J., Chen, T. F., Lin, C. H., Jeng, J. S., Tang, S. C., et al. (2017). Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Scientific Reports, 7(1), 9304.  https://doi.org/10.1038/s41598-017-09009-3.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Ye, B. S., Seo, S. W., Kim, J. H., Kim, G. H., Cho, H., Noh, Y., et al. (2015). Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology, 85(19), 1687–1693.  https://doi.org/10.1212/wnl.0000000000002097.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sung-Chun Tang
    • 1
  • Kai-Chien Yang
    • 2
    • 3
  • Chih-Hao Chen
    • 1
  • Shieh-Yueh Yang
    • 4
  • Ming-Jang Chiu
    • 1
  • Chau-Chung Wu
    • 2
    • 5
  • Jiann-Shing Jeng
    • 1
  1. 1.Department of NeurologyNational Taiwan University HospitalTaipeiTaiwan
  2. 2.Division of Cardiology, Departments of Internal MedicineNational Taiwan University HospitalTaipeiTaiwan
  3. 3.Department and Graduate Institute of PharmacologyNational Taiwan University, College of MedicineTaipeiTaiwan
  4. 4.MagQu Co. Ltd.New Taipei CityTaiwan
  5. 5.Department & Graduate Institute of Medical Education & Bioethics, College of MedicineNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations